SCHEMBL2706462

SCHEMBL2706462

C[C@H](CS)C(=O)OC(=O)C1CCCN1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRCP P42785 1/20 0.35
▸ DPP7 Q9UHL4 1/20 0.35
▸ ACE P12821 3/20 0.33
▸ TLR2 O60603 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ F2 P00734 1/20 0.33
▸ REN P00797 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ LTA4H P09960 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ PEPD P12955 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ PTGS1 P23219 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ PTGS2 P35354 1/20 0.33
▸ HRH1 P35367 1/20 0.33
▸ THPO P40225 1/20 0.33
▸ PMP22 Q01453 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ ACE2 Q9BYF1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL675798 1.00 PRCP (0.35) PRCPDPP7ACETLR2KDM4E
SCHEMBL2422874 1.00 PRCP (0.35) PRCPDPP7ACETLR2KDM4E
SCHEMBL333102 1.00 PRCP (0.35) PRCPDPP7ACETLR2KDM4E
SCHEMBL28911945 1.00 PRCP (0.35) PRCPDPP7ACETLR2KDM4E
SCHEMBL7377621 0.88 DPP7 (0.36) PRCPDPP7TLR2
SCHEMBL28071677 0.86 PRCP (0.33) PRCPDPP7TLR2
SCHEMBL11301923 0.85 PRCP (0.34) PRCPDPP7ACETLR2KDM4E
SCHEMBL10856644 0.85 PRCP (0.35) PRCPDPP7TLR2
SCHEMBL11433291 0.84 CPN1 (0.38) PRCPDPP7TLR2
SCHEMBL11561662 0.84 ACE (0.39) PRCPDPP7ACEREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10940205-B2 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives THEMIS MEDICARE LIMITED (IN) 2021-03-09 — — US disclosed
EP-2446905-B1 Medical device having anti-scarring properties AESCULAP AG (DE) 2019-10-02 — — EP disclosed
US-20180071390-A1 COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES THEMIS MEDICARE LIMITED (IN) 2018-03-15 — — US disclosed
EP-2446905-A1 Medical device having anti-scarring properties Aesculap AG (DE) 2012-05-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180071390-A1 COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES DSG1, DEGS1, PLA2G2E PRCP 4355/4885DPP7 1515/4885ACE 3062/4885
US-10940205-B2 Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives DSG1, DEGS1, PLA2G2E PRCP 4355/4885DPP7 1515/4885ACE 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback